Quantcast

Latest Triple-negative breast cancer Stories

2014-05-14 20:23:48

CLEVELAND, May 14, 2014 /PRNewswire/ -- Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer. The data are being presented at the 50(th) American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago....

2014-04-23 12:29:08

WORCESTER, Mass. and TORONTO, April 23, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that two abstracts in respect of results of the on-going Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer will be presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 30 to June 3, 2014. The ASCO Annual Meeting is the...

2014-04-11 11:57:29

Most breast cancers are treated by blocking their addictions, for example depriving estrogen-fueled tumors of estrogen. But what about breast cancers without these hormonal addictions? In so-called "triple negative" tumors the cancer's addiction remains a mystery, making this subtype difficult to treat. However, a University of Colorado Cancer Center study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2014 showcased a new drug active against...

2014-04-11 10:21:24

ZMYND11 'reads' methylated variant to thwart cancer; tied to breast cancer patient survival A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014. The findings, also published in the journal Nature on April 10, provide evidence in...

2014-04-09 12:31:42

Initiating Phase Ib studies in NSCLC and AML in 2014 BERGEN, Norway, April 9, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that results from its successful Phase Ia clinical study for lead compound, BGB324, was presented at the American Association of Cancer Research annual conference, which took place on April 5-9, 2014. BGB324 is a first-in-class, highly selective small molecule inhibitor...

2014-04-09 08:29:49

SAN FRANCISCO, April 9, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technologies, today announced that preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 Annual Meeting of the American Association of Cancer Research (AACR) being held in San Diego, California. NKTR-102 Presentation Positive preclinical data was presented for NKTR-102...

2014-04-07 12:33:35

The Most Promising Emerging Agents in Development for Triple Negative Breast Cancer Target Only Specific Patient Subsets, According to Findings from Decision Resources Group BURLINGTON, Mass., April 7, 2014 /PRNewswire/ -- Decision Resources Group finds that due to the heterogeneity of triple negative breast cancer the most promising emerging agents in development, target only specific subsets of patients. The two novel emerging therapies niraparib (Tesaro) and Xtandi (Medivation/Astellas)...

2014-03-31 08:30:26

The Jeffrey Epstein VI Foundation funds major discovery to combat triple negative breast cancer. NEW YORK, March 31, 2014 /PRNewswire/ -- Triple negative breast cancer is a particularly aggressive form of breast cancer, highly metastatic and causes about 20% of breast cancer incidences worldwide. Unlike estrogen or progesterone cell surface receptor- type breast cancers, isolating an effective receptor for triple negative breast cancer has yet to be found--to develop a blocking...

2014-03-21 08:24:23

ROCKVILLE, Md., March 21, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three and 12 months ended December 31, 2013. http://photos.prnewswire.com/prnvar/20010620/ENMDLOGO The Company reported a net loss of ($1.3 million), or ($0.05) per share for the three months ended December 31, 2013. This compares with net loss of ($0.4...

2014-03-18 08:33:01

SOUTH SAN FRANCISCO, Calif., March 18, 2014 /PRNewswire/ -- Calithera Biosciences, a clinical-stage biotechnology company focused on the development of novel cancer therapeutics, today announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at the Keystone Symposium on Tumor Metabolism being held in Whistler, Canada from March 16-21, 2014. CB-839 is a potent, selective, orally bioavailable glutaminase inhibitor that interferes with tumor...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'